ALVR Allovir Inc

Price (delayed)

$4.27

Market cap

$279.33M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.93

Enterprise value

$201.41M

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative ...

Highlights
Allovir's debt has soared by 127% YoY but it has decreased by 23% from the previous quarter
The quick ratio has soared by 65% since the previous quarter but it has dropped by 50% year-on-year
The net income has dropped by 102% year-on-year and by 8% since the previous quarter
The equity has declined by 42% year-on-year and by 15% since the previous quarter

Key stats

What are the main financial stats of ALVR
Market
Shares outstanding
65.42M
Market cap
$279.33M
Enterprise value
$201.41M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.46
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$183.9M
EBITDA
-$182M
Free cash flow
-$133.82M
Per share
EPS
-$2.93
Free cash flow per share
-$2.09
Book value per share
$2.93
Revenue per share
$0
TBVPS
$3.61
Balance sheet
Total assets
$231.09M
Total liabilities
$39.42M
Debt
$23.13M
Equity
$191.68M
Working capital
$187.8M
Liquidity
Debt to equity
0.12
Current ratio
11.08
Quick ratio
10.85
Net debt/EBITDA
0.43
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-63.7%
Return on equity
-75%
Return on invested capital
-193.1%
Return on capital employed
-86.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALVR stock price

How has the Allovir stock price performed over time
Intraday
-5.32%
1 week
12.96%
1 month
9.77%
1 year
-79.76%
YTD
-67%
QTD
-36.74%

Financial performance

How have Allovir's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$182.15M
Net income
-$184.9M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 102% year-on-year and by 8% since the previous quarter
The operating income has plunged by 97% YoY and by 7% from the previous quarter

Growth

What is Allovir's growth rate over time

Valuation

What is Allovir stock price valuation
P/E
N/A
P/B
1.46
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALVR's EPS is up by 43% YoY but it is down by 7% QoQ
The price to book (P/B) is 64% less than the last 4 quarters average of 4.1
The equity has declined by 42% year-on-year and by 15% since the previous quarter

Efficiency

How efficient is Allovir business performance
The return on assets has dropped by 115% year-on-year and by 19% since the previous quarter
ALVR's return on equity has dropped by 102% year-on-year and by 23% since the previous quarter
Allovir's return on invested capital has decreased by 20% QoQ

Dividends

What is ALVR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALVR.

Financial health

How did Allovir financials performed over time
ALVR's total liabilities has surged by 88% year-on-year but it is down by 36% since the previous quarter
The current ratio has soared by 66% from the previous quarter but it has contracted by 49% YoY
Allovir's debt is 88% less than its equity
Allovir's debt has soared by 127% YoY but it has decreased by 23% from the previous quarter
The equity has declined by 42% year-on-year and by 15% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.